Cancer is a major health challenge globally and has a serious impact on human health and life, with nearly 20 million new malignancies globally in 2022, an increase of almost 700,000 over 2020 levels. As people are increasingly exposed to a wide range of drugs, it is important to study how these drugs affect cancer incidence, progression and survival. The aim of this study is to explore the impact of neurological and psychiatric drugs, as well as environmental and genetic factors, on cancer outcomes. The study will focus on neurologic medications, including anti-seizure medications, anti-Parkinson’s medications, multiple sclerosis medications, and migraine treatment medications, as well as psychotropic medications such as anxiolytics and antidepressants. The study will also assess the impact of environmental factors (e.g. smoking, alcohol consumption, physical activity and dietary factors) and genetic factors (e.g. polygenic risk scores and other relevant genetic data) on cancer risk and progression. By analyzing detailed data from the UK Biobank, including GP prescriptions, cancer registries, and death records, the study will assess whether these drugs and factors inhibit or promote cancer progression and survival in patients with cancer. The study will utilize comprehensive data linkage to obtain reliable information on drug exposure, cancer incidence and survival outcomes. The study aims to identify potential new uses for existing drugs so that they can be further investigated in randomized controlled trials for the prevention or treatment of cancer. This study is critical to improving cancer treatment and patient prognosis by ensuring that treatment strategies are based on evidence of their impact on cancer progression and survival. The results of the study will be disseminated through peer-reviewed journals and scientific meetings to promote a wider understanding of cancer causes and prevention. The study will adhere to strict ethical standards and maintain participant confidentiality throughout the study.
